Abstract: The present invention relates to viral strains derived from the vaccinia virus Lister VACV-107 and to pharmaceutical composition containing the viral strains. More particularly, the present invention relates to a viral strain derived from the vaccinia virus Lister VACV-107 wherein strain contains in its genomic sequence (SEQ ID N°1) at least one deletion selected from the group consisting of: deletion of the nucleotides 19758 to 28309 in the sequence ID NO°1 (?18), deletion of the nucleotides 161293 to 164811 in the sequence ID NO°1 (?20), deletion of the nucleotides 181231 to 183304 in the sequence ID NO°1 (?21), deletion of the nucleotides 6118 to 9677 in the sequence ID NO°1 (?22), deletion of the nucleotides 1833 to 3574 and 185848 to 187589 in the sequence ID NO°1 (?23).

Abstract: Sterol derivatives of formula (I) and a method for the production of the compounds, a medicament using one of the compounds and a pharmaceutical composition comprising the medicament.

Abstract: The present invention provides polypeptide derivatives of IGFBP-3 that are resistant to proteolytic cleavage. These IGFBP-3 derivatives are useful in a variety of therapeutic and diagnostic applications. Also provided are pharmaceutical compositions and kits comprising such IGFBP-3 derivatives and methods for using these derivatives for the treatment of a variety of disorders.

Abstract: The present invention relates to a method for filtering the signal of neuronal activity during a high frequency deep brain stimulation (DBS) to remove the stimulus artefact in the observed signal, comprising the step of approximating the observed signal trajectories in phase space the observed signal being considered as a sum of the stimulation artifacts induced by the signal of stimulation, wherein the signal of stimulation is assumed to be a solution of an ordinary differential equation including a self-oscillating system with stable limit cycle; slicing the observed signal and its derivative into segments, each segment corresponding to a period of stimulation; collecting N selected periods of stimulation to a training set; estimating the limit cycle of the self-oscillating system; synchronizing each artefact of the observed signal with the estimated limit cycle; subtracting the estimated limit cycle from each artefact in phase space according to the synchronization; collecting all segments in order to obta

Abstract: The present invention concerns a combination of (i) a polypeptide comprising ATIP3 or a biologically active fragment thereof, and (ii) a chemotherapeutic drug that is an antimitotic agent, for simultaneous or sequential use in the treatment of a patient suffering from cancer, e.g. a triple-negative breast cancer. The present invention also relates to a polypeptide comprising ATIP3 or a biologically active fragment thereof, for use in sustaining drug effect, increasing or restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug that is an anti-mitotic agent. The present invention further provides biologically active polypeptides that comprise or consist of fragments of ATIP3, and antibodies binding thereto.

Abstract: The present invention relates to methods and compositions for inhibiting or stimulating angiogenesis. The invention shows the implication of Dp71 in angiogenesis and thus provides novel therapeutic approaches, as well as novel methods for screening agents modulating angiogenesis, which target this protein. More specifically, the present invention relates to the use of Dp71 or a variant thereof (or a coding nucleic acid) for stimulating angiogenesis in a subject, particularly a human subject. The invention relates to the use of an inhibitor of Dp71 for inhibiting angiogenesis in a subject.

Abstract: The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.

Abstract: The invention relates to the use of antagonists to the CB1 receptor for the preparation of a composition for the treatment of hepatic diseases and preferably to the use of N-piperidino5 5-(4-chlorophenyl)-1-(2, 4-dichloropenyl)-4-methylpyrazole-3-carboxamide.

Abstract: The present invention concerns a C-glucosidic ellagitannin compound or a metabolite thereof for use for altering the supramolecular arrangement of actin in an individual suffering from osteoporosis, cancer, bacterial infection, or viral infection. It also pertains to pharmaceutical compositions comprising a C-glucosidic ellagitannin compound and/or metabolites thereof and one or more physiologically acceptable carriers. It finally concerns a C-glucosidic ellagitannin compound or a metabolite thereof, optionally detectably labeled, for in vitro use as a tool for studying cellular mechanisms involving actin, or for detecting F-actin in a cell.

Abstract: The invention relates to the use of cystamine, cysteamine, or a salt thereof, or of calcineurin inhibitors for treating a MeCP2-associated disorder such as Rett syndrome.

Abstract: The invention relates to a method for evaluating the vital prognosis of a subject suffering from heart failure, said method comprising the step of determining the lactate/cholesterol ratio in a biological sample of said subject and comparing the lactate/cholesterol ratio to a threshold value.

Abstract: The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient.

Abstract: The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from said subject wherein the level of EF1 is negatively correlated with the risk of said subject of having cardiovascular disease.

Abstract: The invention relates a method for diagnosing asymptomatic left ventricular systolic dysfunction in a subject comprising the step a) of: —measuring the level of expression of the genes FECH, TMEM79, FBXW7, NGFB, ALK, UBN1 and SLC43A2 in a biological sample of said subject; or—measuring the level of expression of at least one gene selected from the group consisting of FECH, TMEM79, FBXW7, NGFB, ALK, UBN1 and SLC43A2 in a biological sample of said subject.

Abstract: The present invention relates to methods for the treatment, the prognostic assessment and the detection of breast cancer.

Abstract: The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.

Abstract: The present invention relates to methods for restoring the function of a mutated dysferlin comprising the step of preventing splicing of one or more exons which encode amino acid sequences that cause said dysferlin dysfunction. Particularly, the splicing of exon 32 is prevented. The present invention also relates to a method for treating a dysferlinopathy in a patient in need thereof, comprising the step of administering to said patient antisense oligonucleotides complementary to nucleic acid sequences that are necessary for correct splicing of one or more exons which encode amino acid sequences that cause said dysfunction. Particularly, the splicing of exon 32 is prevented.

Abstract: The invention related to chimeric peptides including a penetrating peptide and a binding domain of PP2A catalytic subunit to caspase-9 which have pro-apoptotic activity. These chimeric peptides may be used for the treatment of hyperproliferative disorders.

Abstract: The invention relates to serotonin 5-HT3 receptor antagonists or inhibitors of serotonin 5-HT3 receptor gene expression for use in the treatment of a lesional vestibular disorder.

Abstract: An in vitro method for diagnosing a breast cancer from the luminal-B subtype in a female, includes the steps of analyzing a biological sample from the female by (i) determining the copies number of the ZNF703 gene, and/or (ii) determining the expression of the ZNF703 gene, wherein an increased copies number and/or an over-expression of the ZNF703 gene is indicative of a luminal B tumor; to a kit for diagnosing a breast cancer from the luminal-B subtype in a female including at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a method as defined previously, for determining the copies number of the ZNF703 gene, and/or determining the expression of the ZNF703 gene; and to the use of such a kit.